Skip to search formSkip to main contentSkip to account menu

Phosphodiesterase 5 inhibitor

Known as: Phosphodiesterase V Inhibitor, Inhibitors, PDE5, PDE 5 Inhibitors 
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
National Institutes of Health

Related topics

Related topics

11 relations
In Bloodaspects of radiation effectscGMP Phosphodiesterase Inhibitorchemical synthesis

Broader (1)

Phosphodiesterase 5 Inhibitor [EPC]

Narrower (5)

Sildenafil citratemirodenafiltadalafiludenafil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
Review
2014
Review
2014
Targeted therapies in pulmonary arterial hypertension.
Highly Cited
2010
Highly Cited
2010
Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction.
Highly Cited
2009
Highly Cited
2009
Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome.
INTRODUCTION Metabolic syndrome (MetS) is a clustering of cardio-metabolic risk factors (hyperglycemia, hypertension… 
Highly Cited
2008
Highly Cited
2008
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
The pulmonary vascular bed is both a source of and target for a number of vasoactive factors. Among the most important for… 
Review
2004
Review
2004
Neural control of erection
Highly Cited
2004
Highly Cited
2004
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
PURPOSE Tadalafil, a phosphodiesterase type 5 inhibitor, is effective therapy for erectile dysfunction (ED). Men with ED have a… 
Highly Cited
2003
Highly Cited
2003
Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension
Background—Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmonary hypertension. This study… 
Highly Cited
2002
Highly Cited
2002
The Phosphodiesterase 5 Inhibitor Sildenafil Has No Effect on Cerebral Blood Flow or Blood Velocity, but Nevertheless Induces Headache in Healthy Subjects
Cyclic nucleotides are important hemodynamic regulators in many tissues. Glyceryl trinitrate markedly dilates large cerebral… 
Review
1999
Review
1999
Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.
Investigations of recent years revealed that isozymes of cyclic-3', 5'-nucleotide phosphodiesterase (PDE) are a critically… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)